title: Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial.
abstract: OBJECTIVE
  This study aimed to test the efficacy of mesalazine in maintaining remission in pediatric Crohn's disease (CD) following successful flare-up treatment.
  
  
  METHODS
  In this double-blind, randomized, placebo-controlled trial, 122 patients received either mesalazine 50mg/kg per day (n=60) or placebo (n=62) for one year. Treatment allocation was stratified according to flare-up treatment (nutrition or medication alone). Recruitment was carried out over two periods, as the first period's results showed a trend favoring mesalazine. Relapse was defined as a Harvey-Bradshaw score more than or equal to 5. Time to relapse was analyzed using the Cox model.
  
  
  RESULTS
  The one-year relapse rate was 57% (n=29) and 63% (n=35) in the mesalazine and placebo groups, respectively. We demonstrated a twofold lower relapse risk (P<0.02) in patients taking mesalazine in the medication stratum (first recruitment period), and a twofold higher risk in patients taking mesalazine in the nutrition stratum (second recruitment period), compared with the other groups. None of the children's characteristics, which differed across the two recruitment periods, accounted for the between-period variation in mesalazine efficacy. One serious adverse event was reported in each treatment group.
  
  
  CONCLUSIONS
  Overall, mesalazine does not appear to be an effective maintenance treatment in pediatric CD.
authors.affiliation: Service de gastroentérologie pédiatrique, mucoviscidose, nutrition pédiatrique, centre de référence des maladies digestives rares de l'enfant, hôpital Robert-Debré, 75019 Paris cedex 19, France. jean-pierre.cezard@rdb.aphp.fr
authors.forename: J-P
authors.initials: JP
authors.lastname: Cezard
authors.forename: A
authors.initials: A
authors.lastname: Munck
authors.forename: O
authors.initials: O
authors.lastname: Mouterde
authors.forename: A
authors.initials: A
authors.lastname: Morali
authors.forename: C
authors.initials: C
authors.lastname: Lenaerts
authors.forename: A
authors.initials: A
authors.lastname: Lachaux
authors.forename: D
authors.initials: D
authors.lastname: Turck
authors.forename: J
authors.initials: J
authors.lastname: Schmitz
authors.forename: C
authors.initials: C
authors.lastname: Maurage
authors.forename: J-P
authors.initials: JP
authors.lastname: Girardet
authors.forename: D
authors.initials: D
authors.lastname: Belli
authors.forename: T
authors.initials: T
authors.lastname: Lamireau
authors.forename: J
authors.initials: J
authors.lastname: Sarles
authors.forename: J-P
authors.initials: JP
authors.lastname: Chouraqui
authors.forename: B
authors.initials: B
authors.lastname: Descos
authors.forename: A
authors.initials: A
authors.lastname: Dabadi
authors.forename: M
authors.initials: M
authors.lastname: Meyer
authors.forename: J-P
authors.initials: JP
authors.lastname: Olives
authors.forename: J-Y
authors.initials: JY
authors.lastname: Mary
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000627:therapeutic use*; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine